| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 42, 545-550, Copyright © 1996 by American Association for Clinical Chemistry
F Espana, J Sanchez-Cuenca, A Estelles, J Gilabert, JH Griffin and MJ Heeb
Research Center, La Fe Univesity Hospital, Valencia, Spain.
We have developed two ELISAs for quantifying complexes of prostate- specific antigen (PSA) with alpha2-macroglobulin (alpha2M), using partially purified PSA:alpha2M complex as the calibrator. One ELISA was designed to evaluate )SA:alpha2M complex in fluids containing a huge excess of PSA over the amount of complex (semen-derived fluids), the other for use in fluids containing an excess of alpha2M over PSA (blood plasma). The range of the assays was 2-1000 micrograms/L for PSA complexed to alpha2M; the detection limit was 3 micrograms/: Intra- and interassay CVs were 7-13% and 11-17%, respectively, at complexed PSA concentrations of 6-500 micrograms/L. Seminal fluid from healthy men (n = 60) contained 5.2 +/- 2.6 micrograms/L PSA complexed with alpha2M. Prostatic and seminal vesicle fluids contained 6.5 +/- 2.9 ad 0.3 +/- 0.2 mg/L PSA complexed to alpha2M, respectively. When purified PSA was incubated with citrated plasma, between 45% and 65% of the added PSA was recovered as free PSA, whereas approximately 25% formed complexes with alpha2M, 10% complexed with alpha1-antichymotrypsin, and only 0.1- 6% was complexed with protein C inhibitor. Of 30 patients with prostate disease, 20 showed detectable plasma PSA:alpha2M complexes; however, the potential diagnostic significance of this complex requires further investigation.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  M. Martinez, F. Espana, M. Royo, J. M. Alapont, S. Navarro, A. Estelles, J. Aznar, C. D. Vera, and J. F. Jimenez-Cruz The Proportion of Prostate-specific Antigen (PSA) Complexed to {alpha}1-Antichymotrypsin Improves the Discrimination between Prostate Cancer and Benign Prostatic Hyperplasia in Men with a Total PSA of 10 to 30 {micro}g/L Clin. Chem., August 1, 2002; 48(8): 1251 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147. [Abstract] [Full Text]
|
|
|
|
|
|
D. W. Chan and L. J. Sokoll Prostate-specific Antigen: Advances and Challenges Clin. Chem., June 1, 1999; 45(6): 755 - 756. [Full Text] [PDF]
|
|
|
|
|
|
S. Michel, G. Deleage, J.-P. Charrier, J. Passagot, N. Battail-Poirot, G. Sibai, M. Jolivet, and C. Jolivet-Reynaud Anti-Free Prostate-specific Antigen Monoclonal Antibody Epitopes Defined by Mimotopes and Molecular Modeling Clin. Chem., May 1, 1999; 45(5): 638 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-M. Zhang, P. Finne, J. Leinonen, S. Vesalainen, S. Nordling, S. Rannikko, and U.-H. Stenman Characterization and immunological determination of the complex between prostate-specific antigen and {alpha}2-macroglobulin Clin. Chem., December 1, 1998; 44(12): 2471 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Y. Cheung, D. J. Green, G. J. Litt, and J. A. Laugharn Jr. High-pressure-mediated dissociation of immune complexes demonstrated in model systems Clin. Chem., February 1, 1998; 44(2): 299 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Qian, J. A. Sensibar, D. J. Zelner, A. J. Schaeffer, J. A. Finlay, H. G. Rittenhouse, and C. Lee Two-dimensional gel electrophoresis detects prostate-specific antigen–{alpha}1-antichymotrypsin complex in serum but not in prostatic fluid Clin. Chem., February 1, 1997; 43(2): 352 - 359. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
